Outcomes for Absorb Stent Acceptable at One to Two Years, with Caveats

Patients receiving the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS), a dissolving stent to open clogged vessels around the heart, showed outcomes comparable with patients receiving the Xience drug-eluting metal stent between years one and two. Ellis S
However, patients receiving Absorb BVS faced an overall elevated risk of adverse outcomes at two years compared with patients receiving metal stents, a difference that appears to be attributable to the stent being placed in vessels that were smaller than recommended, according to a study presented at the American College of Cardiology’s 66th Annual Scientific Session. American College of Cardiology, ACC’s Annual Scientific Session 2017